a privately held biotechnology company, and held various financial and strategic management positions at publicly traded biotechnology companies including Dendreon and Amgen. Ms. Eastland is an ...
In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Amgen (AMGN – Research Report). The company’s ...
As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...
Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
GlobalData on MSN19h
Amgen speaks out about bone density concerns with obesity drugAmgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...
Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday, Nov. 13, 2024.
News Medical on MSN2d
deCODE genetics/Amgen: New Study Explores the Role of BMI in Disease RiskNew study from deCODE genetics/Amgen highlights the importance of BMI in pathogenesis of disease, suggesting that reducing ...
Zacks.com on MSN12h
Amgen Shrugs Off Bone Density Concerns Related to Obesity CandidateKey Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback